Chunghwa Chemical Synthesis & Biotech Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Chunghwa Chemical Synthesis & Biotech.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals earnings growth | 48.0% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 28 Mar 2024 |
Recent future growth updates
Recent updates
Chunghwa Chemical Synthesis & Biotech Co., Ltd.'s (TWSE:1762) Business And Shares Still Trailing The Industry
Aug 09
Chunghwa Chemical Synthesis & Biotech's (TWSE:1762) Dividend Is Being Reduced To NT$0.80
Jul 12Chunghwa Chemical Synthesis & Biotech's (TWSE:1762) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Apr 04A Look At The Intrinsic Value Of Chunghwa Chemical Synthesis & Biotech Co., Ltd. (TPE:1762)
Apr 01Chunghwa Chemical Synthesis & Biotech Co., Ltd.'s (TPE:1762) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Mar 04What To Know Before Buying Chunghwa Chemical Synthesis & Biotech Co., Ltd. (TPE:1762) For Its Dividend
Jan 28Should You Rely On Chunghwa Chemical Synthesis & Biotech's (TPE:1762) Earnings Growth?
Jan 02The Chunghwa Chemical Synthesis & Biotech (TPE:1762) Share Price Is Up 131% And Shareholders Are Boasting About It
Dec 06In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Chunghwa Chemical Synthesis & Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2024 | 1,730 | 207 | 202 | 452 | 1 |
| 6/30/2024 | 1,507 | 118 | -161 | -2 | N/A |
| 3/31/2024 | 1,573 | 126 | -472 | -306 | N/A |
| 12/31/2023 | 2,086 | 265 | -518 | -66 | N/A |
| 9/30/2023 | 2,173 | 290 | -468 | 69 | N/A |
| 6/30/2023 | 2,300 | 399 | -96 | 435 | N/A |
| 3/31/2023 | 2,353 | 517 | -16 | 578 | N/A |
| 12/31/2022 | 2,117 | 466 | 358 | 734 | N/A |
| 9/30/2022 | 2,082 | 488 | 309 | 685 | N/A |
| 6/30/2022 | 2,122 | 452 | 136 | 541 | N/A |
| 3/31/2022 | 2,043 | 430 | -222 | 257 | N/A |
| 12/31/2021 | 1,935 | 401 | -186 | 219 | N/A |
| 9/30/2021 | 1,987 | 408 | -222 | 86 | N/A |
| 6/30/2021 | 1,766 | 358 | -198 | 107 | N/A |
| 3/31/2021 | 1,658 | 602 | 30 | 230 | N/A |
| 12/31/2020 | 1,544 | 532 | -55 | 138 | N/A |
| 9/30/2020 | 1,260 | 470 | 28 | 212 | N/A |
| 6/30/2020 | 1,193 | 461 | 118 | 267 | N/A |
| 3/31/2020 | 1,120 | 104 | 150 | 261 | N/A |
| 12/31/2019 | 1,157 | 117 | 153 | 268 | N/A |
| 9/30/2019 | 1,113 | 76 | 108 | 231 | N/A |
| 6/30/2019 | 1,074 | 270 | 87 | 199 | N/A |
| 3/31/2019 | 1,087 | 272 | 27 | 140 | N/A |
| 12/31/2018 | 1,019 | 234 | 141 | 235 | N/A |
| 9/30/2018 | 1,131 | 286 | -267 | 318 | N/A |
| 6/30/2018 | 1,313 | 129 | -441 | 349 | N/A |
| 3/31/2018 | 1,172 | 101 | N/A | 260 | N/A |
| 12/31/2017 | 1,168 | 86 | N/A | 159 | N/A |
| 9/30/2017 | 1,126 | 67 | N/A | 160 | N/A |
| 6/30/2017 | 1,100 | 19 | N/A | 141 | N/A |
| 3/31/2017 | 1,204 | 31 | N/A | 224 | N/A |
| 12/31/2016 | 1,199 | 60 | N/A | 261 | N/A |
| 9/30/2016 | 1,254 | 94 | N/A | 218 | N/A |
| 6/30/2016 | 1,185 | 112 | N/A | 223 | N/A |
| 3/31/2016 | 1,181 | 125 | N/A | 254 | N/A |
| 12/31/2015 | 1,162 | 308 | N/A | 80 | N/A |
| 9/30/2015 | 1,098 | 246 | N/A | 92 | N/A |
| 6/30/2015 | 995 | 193 | N/A | -48 | N/A |
| 3/31/2015 | 945 | 203 | N/A | -55 | N/A |
| 12/31/2014 | 947 | 15 | N/A | 23 | N/A |
| 9/30/2014 | 923 | 17 | N/A | -4 | N/A |
| 6/30/2014 | 965 | 46 | N/A | 103 | N/A |
| 3/31/2014 | 995 | 67 | N/A | 124 | N/A |
| 12/31/2013 | 1,043 | 97 | N/A | 145 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 1762's forecast earnings growth is above the savings rate (1%).
Earnings vs Market: Insufficient data to determine if 1762's earnings are forecast to grow faster than the TW market
High Growth Earnings: Insufficient data to determine if 1762's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if 1762's revenue is forecast to grow faster than the TW market.
High Growth Revenue: Insufficient data to determine if 1762's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 1762's Return on Equity is forecast to be high in 3 years time